Consensus ($1.30). Raises FY23 revenue view to $130M-$132M from $103M-$106M, consensus $116.95M. The company said, “Surmodics now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the prior year. The company’s prior guidance called for fiscal year 2023 total revenue of $103 million to $106 million, representing an increase of 3% to 6% compared to the prior year. The company now expects fiscal 2023 GAAP diluted loss per share to range from $(0.55) to $(0.40). The company’s prior guidance called for fiscal 2023 GAAP diluted loss per share of $(2.30) to $(2.00). Non-GAAP diluted loss per share in fiscal 2023 is expected to range from $(0.29) to $(0.14). The company’s prior guidance called for fiscal 2023 Non-GAAP diluted loss per share of $(1.98) to $(1.68).”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SRDX:
- Surmodics price target raised to $69 from $60 at Barrington
- Surmodics announces FDA approval of SurVeil drug-coated balloon
- Surmodics gets FDA clearance for Pounce Thrombectomy System
- Surmodics upgraded to Buy at Needham on positive SurVeil developments
- Surmodics upgraded to Buy from Hold at Needham